Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Xylyx Bio Inc. currently manages 2 pending office actions within the Chemistry & Materials technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, indicating a spread of oversight relative to the volume of active cases. This distribution suggests that each application is being evaluated independently within separate administrative divisions of the patent office. The lack of concentration in a single art unit may require the legal team to adapt to different procedural styles across the Chemistry & Materials sector.
HOLLY MICHAELA KIPOUROS is the busiest examiner for the portfolio, responsible for 1 busiest examiner pending action. The alignment of 2 distinct examiners with 2 distinct art units implies that no single examiner or art unit holds a majority of the company's current legal challenges. Practitioners should prepare for varied feedback across these different technical groups, as the 2 distinct examiners likely bring unique perspectives to the 2 pending office actions. This diversity in examination can provide broader insights into how different departments interpret the company's innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIPOUROS, HOLLY MICHAELA | 1 | 69.5% | +21.6% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| PHILIPOSE, HANNAH SARAH | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997829 | DEVICES AND METHODS FOR IN VITRO MODELING OF METASTATIC CANCER | KIPOUROS, HOLLY MICHAELA | — |
| 17629046 | FIBROSIS-SPECIFIC CELL CULTURE SUBSTRATE AND METHODS OF USE | PHILIPOSE, HANNAH SARAH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021660 | TISSUE-DERIVED MATRIKINE COMPOSITIONS AND METHODS THEREFOR | SABILA, MERCY HELLEN | 73d overdue |
| 17997829 | DEVICES AND METHODS FOR IN VITRO MODELING OF METASTATIC CANCER | KIPOUROS, HOLLY MICHAELA | — |
| Art Unit | Apps |
|---|---|
| 1799 | 1 |
| 1654 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17997829 | DEVICES AND METHODS FOR IN VITRO MODELING OF METASTATIC CANCER | KIPOUROS, HOLLY MICHAELA | 1799 | §102§103 | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18021660 | TISSUE-DERIVED MATRIKINE COMPOSITIONS AND METHODS THEREFOR | SABILA, MERCY HELLEN | 1654 | §103 | Final Rejection | 73d overdue | Pending | Feb 16, 2023 |
| 17629046 | FIBROSIS-SPECIFIC CELL CULTURE SUBSTRATE AND METHODS OF USE | PHILIPOSE, HANNAH SARAH | 1631 | §101§102§103§112 | Final Rejection | — | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial